| Patents for A61K 9 - Medicinal preparations characterised by special physical form (299,044) |
|---|
| 03/11/2004 | WO2004019903A1 Buccal, polar and non-polar spray or capsule containing drugs fortreating metabolic disorders |
| 03/11/2004 | WO2004019902A1 Adhesive gel composition for iontophoresis preparation and process for producing the same |
| 03/11/2004 | WO2004019901A2 Sustained release pharmaceutical composition |
| 03/11/2004 | WO2004019892A2 Drug delivery system for treating urinary incontinence |
| 03/11/2004 | WO2004019890A2 In vivo production of cyclic peptides for inhibiting protein-protein interaction |
| 03/11/2004 | WO2004019885A2 Fast dissolving film delivery of nucleotides that inhibit the unpleasant taste of bitter tasting medications |
| 03/11/2004 | WO2004019871A2 Breath freshening and oral cleansing product using geraniol |
| 03/11/2004 | WO2004019870A2 Breath freshening and oral cleansing product using salicylaldehyde |
| 03/11/2004 | WO2004019867A2 Breath freshening and oral cleansing product using cardamom oil |
| 03/11/2004 | WO2004019865A2 Amelioration of effects of cigarette smoke |
| 03/11/2004 | WO2004019853A2 Dosage forms having reduced moisture transmission |
| 03/11/2004 | WO2004019837A1 Medicinal product packaging |
| 03/11/2004 | WO2004019758A2 Methods of treating idiopathic pulmonary fibrosis |
| 03/11/2004 | WO2004004705A3 Pharmaceutical formulations for preparing drink products |
| 03/11/2004 | WO2004002444A3 A platform for transdermal formulations (ptf) |
| 03/11/2004 | WO2004000219A3 Stabilized formulations of alpha adrenergic receptor antagonists and uses thereof |
| 03/11/2004 | WO2003104192A3 Controlled release formulation of lamotrigine |
| 03/11/2004 | WO2003099200A3 Composition and method for the treatment of diaper rash using natural products |
| 03/11/2004 | WO2003093449A3 Methods for delivery of nucleic acids |
| 03/11/2004 | WO2003090715A3 Particulate materials |
| 03/11/2004 | WO2003084520A3 Pharmaceutical preparation containing oxycodone and naloxone |
| 03/11/2004 | WO2003084504A3 Matrix for sustained, invariant and independent release of active compounds |
| 03/11/2004 | WO2003072020A9 Therapeutical polyanhydride compounds for drug delivery |
| 03/11/2004 | WO2003070161A3 Emulsified skin care composition containing salicylic acid, lanolin oil, and propylene glycol |
| 03/11/2004 | WO2003066585A3 Polymer-based compositions for sustained release |
| 03/11/2004 | WO2003066019A3 Method for producing water dispersible dry powders from poorly soluble compounds |
| 03/11/2004 | WO2003064993A3 Methods and materials for detecting genetic material |
| 03/11/2004 | WO2003061635A3 Method and device for producing products in web form |
| 03/11/2004 | WO2003061617A3 Method for treatment of a region of the skin of a human subject, in particular cosmetic treatment by the trans-epidermal route using projection of a liquid under pressure |
| 03/11/2004 | WO2003059323A3 Stable salts of o-acetylsalicylic acid containing basic amino acids ii |
| 03/11/2004 | WO2003057133A3 Herbal composition for treating various disorders including psoriasis, a process for preparation thereof and method for treatment of such disorders |
| 03/11/2004 | WO2003045350A3 Device for incorporating substances which contain a sea sponge as a support |
| 03/11/2004 | WO2003037301A3 Oral dosage forms for improving the bioavailability of therapeutic agents |
| 03/11/2004 | WO2003035051A3 The use of proton sequestering agents in drug formulations |
| 03/11/2004 | WO2003035034A3 Powder for nasal administration of drugs |
| 03/11/2004 | WO2003034902A3 Method and system for non-vascular sensor implantation |
| 03/11/2004 | WO2003028760A3 Vaccine |
| 03/11/2004 | WO2003028653A3 Sustained release pharmaceutical compositions |
| 03/11/2004 | WO2003022326A3 Infusion device and driving mechanism for same |
| 03/11/2004 | WO2003015690B1 Method for treating primary insomnia |
| 03/11/2004 | WO2003014316A3 Immunomodulatory compositions, formulations, and methods for use thereof |
| 03/11/2004 | WO2003011294A3 Mucin synthesis inhibitors |
| 03/11/2004 | WO2003006608A3 Enhancement of transfection of dna into the liver |
| 03/11/2004 | WO2003000191A3 Composition comprising glycosaminogycans and hyaluronidase inhibitors for the treatment of arthritic joints |
| 03/11/2004 | WO2002085428A3 Implantable osmotic pump |
| 03/11/2004 | WO2002082462A3 Stabilization and terminal sterilization of phospholipid formulations |
| 03/11/2004 | WO2002070594A8 A method of preparing a collagen sponge, a device for extracting a part of a collagen foam, and an elongated collagen sponge |
| 03/11/2004 | WO2002058750A8 A suspension comprising fibrinogen, thrombin and alcohol and a method of coating a carrier with the same |
| 03/11/2004 | WO2002058749A8 Carrier with solid fibrinogen and solid thrombin |
| 03/11/2004 | US20040049265 Drug coating with topcoat |
| 03/11/2004 | US20040049240 Electrical and/or magnetic stimulation therapy for the treatment of prostatitis and prostatodynia |
| 03/11/2004 | US20040049187 Self-adhesive hydratable matrix for topical therapeutic use |
| 03/11/2004 | US20040049150 Vaccines |
| 03/11/2004 | US20040049045 Process for the crystallization of (r)-or (s)-lansoprazole |
| 03/11/2004 | US20040048934 Self-emulsifying drug delivery system |
| 03/11/2004 | US20040048933 Autonomic nerve regulating agent |
| 03/11/2004 | US20040048932 Anesthetic e.g., sevoflurane, enflurane, isoflurane, methoxyflurane, or desflurane, containing a Lewis acid inhibitor |
| 03/11/2004 | US20040048931 Modafinil pharmaceutical compositions |
| 03/11/2004 | US20040048929 E.g., N-(4-fluorophenylsulfonyl)-L-valyl-L-leucinal stabilized with a lipid; improved absorption and penetration; treating ischemia, immune diseases, Alzheimer's disease, osteoporosis, brain disorders, eye diseases, osteoporosis |
| 03/11/2004 | US20040048924 Ibuprofen composition |
| 03/11/2004 | US20040048906 Synergistic combinations of amlodipine and atorvastatin used to treat angina pectoris, atherosclerosis, combined hypertension and hyperlipidemia and to treat subjects with symptoms of cardiac risk |
| 03/11/2004 | US20040048902 Medicinal preparation containing 5-methyl-1-phenyl-2-(1h)-pyridone as active ingredient |
| 03/11/2004 | US20040048896 Treating gastric acid disorders by orally administering a proton pump inhibitor and a mixture of buffers |
| 03/11/2004 | US20040048877 Pharmaceutical compositions containing flibanserin |
| 03/11/2004 | US20040048836 Method for preparing high pressure/ high shear dispersions containing physiologically active ingredients |
| 03/11/2004 | US20040048831 Verifiable absorption drug delivery form based on cyclodextrins |
| 03/11/2004 | US20040048828 Immunosuppressive agent and food |
| 03/11/2004 | US20040048822 Nucleic acid immunization |
| 03/11/2004 | US20040048814 Sustained release composition contraining clarithromycin |
| 03/11/2004 | US20040048812 Health supplement |
| 03/11/2004 | US20040048809 Micronized digoxin, hydrophilic polymer(s) (e.g., hydroxypropyl methyl cellulose) and optional excipient(s) in the form of a tablet that releases not more than 50% digoxin in 5 minutes and at least 85% digoxin in 60 minutes. |
| 03/11/2004 | US20040048790 Inducing cellular immune responses to p53 using peptide and nucleic acid compositions |
| 03/11/2004 | US20040048789 Pharmaceutical compositions |
| 03/11/2004 | US20040048787 Lyophilizable and enhanced compacted nucleic acids |
| 03/11/2004 | US20040048786 Antibiotic coating for porous bodies and method for its production as well as its use |
| 03/11/2004 | US20040048783 Acidic insulin preparations having improved stability |
| 03/11/2004 | US20040048782 Colloidal suspension of submicronic particles for carrying hydrophilic active principles (insulin) and method for preparing same |
| 03/11/2004 | US20040048777 Compounds and compositions for delivering active agents |
| 03/11/2004 | US20040048772 Preventives for arthritis |
| 03/11/2004 | US20040048768 Forming a solution from a liquid and an antimicrobial agent; combining a cellulosic fibrous material with solution to form a liquid suspension forming a web from liquid suspension |
| 03/11/2004 | US20040048358 Consistent and effective encapsulation of viable biological material with a polymeric coating material to form a gelled capsule, which can be transplanted into genetically dissimilar hosts |
| 03/11/2004 | US20040048289 A protein specific to a magnetic particle membrane, DNA which encodes the protein and their uses |
| 03/11/2004 | US20040048018 Firm balls and toys with slow rebound characteristics |
| 03/11/2004 | US20040047930 For topical application |
| 03/11/2004 | US20040047916 Compositions and methods for the treatme of primary and metastatic neoplastic disea using arsenic compounds |
| 03/11/2004 | US20040047911 Versatility and tunability in controlling the delivery of active agents |
| 03/11/2004 | US20040047910 Suppository and composition comprising at least one polyethylene glycol |
| 03/11/2004 | US20040047908 For inducing or maintaining sleep |
| 03/11/2004 | US20040047907 Controlled release hydrocodone formulations |
| 03/11/2004 | US20040047906 Dosage form, such as a capsule or the like for delivering drugs into the body in a circadian release fashion; chronotherapy for cardiovascular diseases |
| 03/11/2004 | US20040047904 Amino acid-containing tablets quickly disintegrating in the oral cavity and process for producing the same |
| 03/11/2004 | US20040047903 For use in therapy of cancer |
| 03/11/2004 | US20040047901 Storage stability |
| 03/11/2004 | US20040047895 Laver protein-containing composition and foods |
| 03/11/2004 | US20040047893 Method for preventing crystal formation in a dispersion of a liquid in a matrix |
| 03/11/2004 | US20040047890 Containing the viable cells, or tissue comprising the viable cells, prior to transplantation within a device comprising a semipermeable membrane; treating subject with a substance which inhibits an immune-system costimulation |
| 03/11/2004 | US20040047888 Providing implanter for implanting parasiticidal pellets; loading pellet magazine with immediate release parasiticidal agent pellet dose and extended release dose; inserting hypodermic needle under skin of an animal's ear to inject |
| 03/11/2004 | US20040047885 Use of compounds which make it possible to modify the physicochemical properties of the skin and/or the mucous membranes as agents preventing or reducing the adhesion of microorganisms to the latter |
| 03/11/2004 | US20040047878 DNA vaccine against feline immunodeficiency virus |
| 03/11/2004 | US20040047872 Indicators for monitoring the technique of transcutaneous immunization |